Plain-English translation of NCT05977023 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing an NMDA enhancer — a medication that works on a specific brain chemical — to see if it can help people with bipolar I disorder who are struggling with depression despite being on other medications. The study focuses on whether this treatment can improve problems with thinking and memory, and reduce stress. You would take the medication (or a placebo) for 8 weeks while continuing your regular bipolar treatment.
People with bipolar I disorder often have depression that doesn't fully respond to current treatments, and they frequently experience cognitive problems — like trouble with memory and concentration — that affect their daily lives. This medication may offer a new way to address both the depression and these thinking difficulties.
You likely qualify if…
You likely don't qualify if…
You will continue taking your regular bipolar medications and visit the research clinic at baseline and then at weeks 2, 4, 6, and 8. At each visit, you'll either receive the new medication or a placebo (you won't know which), plus you'll complete questionnaires and cognitive tests to measure changes in your thinking, mood, stress levels, and quality of life. The entire study lasts 8 weeks.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Taiwan